Eli Lilly has announced a major policy change for participants in the 340B Drug Pricing Program, effective February 1, 2026. Moving forward, covered entities will be required to submit claims data for all Lilly drugs dispensed through in‑house pharmacies...
On December 19, 2025, President Trump announced new Most-Favored-Nation (MFN) drug pricing agreements with nine additional major pharmaceutical manufacturers, these include GSK, Sanofi, Genentech, Amgen, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Novartis, Gilead and Merck. These agreements aim to...
Major changes will impact healthcare and drug pricing in 2026 – from new federal pricing policies and regulations to a surge of high-impact drug launches. At ProAct, we’re already preparing...
On December 22nd, the Food and Drug Administration (FDA) approved Novo Nordisk’s oral semaglutide tablet, a 25 mg dose of the same active ingredient found in injectable Wegovy and Ozempic. Marketed under the brand name Wegovy, the tablet...
On November 25, 2025, the Centers for Medicare & Medicaid Services (CMS) released negotiated maximum fair prices (MFPs) for 15 high-cost Medicare Part D drugs under the Inflation Reduction Act, effective January 1, 2027. The drugs selected...
